MRNA stock forecast, quote, news & analysis
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018... Show more
Moderna, Inc. (MRNA) Stock Analysis: Pipeline Wins Amid Earnings Anticipation
Key Takeaways
- Moderna's shares have delivered strong year-to-date gains of around 65%, reflecting optimism in its mRNA (messenger RNA) platform despite recent volatility.
- European Commission approved Moderna's COVID-19/influenza combo vaccine, a key milestone boosting its seasonal vaccine franchise.
- Phase 3 trial initiated for mRNA pandemic influenza vaccine, expanding respiratory portfolio.
- Q1 2026 earnings due May 1, with expectations for year-over-year sales growth but potential negative EPS (earnings per share).
- Analyst consensus holds at "Hold" with average price target near $46, below recent trading levels.
- Strong balance sheet with $5.8 billion in cash supports ongoing R&D (research and development).
Current Market Snapshot
In recent trading sessions, Moderna stock has exhibited volatility within its 52-week range of $22.28 to $59.55, underpinned by robust year-to-date advances exceeding 65% but tempered by a pullback over the past week. Trading around the $48 to $50 level, the shares have outperformed broader indices over longer periods, driven by pipeline catalysts in the mRNA space. Investor focus remains on upcoming earnings and regulatory progress amid a shifting post-pandemic landscape for vaccine makers. Market cap hovers near $19 billion, with elevated short interest signaling mixed sentiment.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from hundreds available that trade thousands of tickers across diverse strategies. These bots employ varied approaches, including pattern recognition, swing trading, and sector-specific models, with timeframes from intraday to long-term holds. Standouts have delivered annualized returns up to 135% in high-growth sectors, success rates exceeding 73%, and win rates as high as 88% in ETF strategies. Optimized for current market conditions like volatility in biotech, they offer real-time trade alerts, stop-loss features, and performance stats to help investors navigate stocks like MRNA. Explore these tools for data-driven insights tailored to today's environment.
Recent Developments Driving MRNA Price Action
Moderna's stock has navigated choppy waters in recent weeks, with a notable weekly decline of about 9-10% despite positive pipeline news, as investors weigh earnings risks against innovation momentum. A pivotal catalyst emerged on April 21-22 when the European Commission granted marketing authorization for Moderna's investigational COVID-19/influenza combination vaccine, mRNA-1083. This approval positions the shot as a potential cornerstone for the company's seasonal respiratory franchise, addressing the need for convenient combo immunizations and expanding beyond standalone COVID products. The news highlighted Moderna's progress in diversifying its portfolio post-pandemic, contributing to intraday gains before broader market pressures pulled shares lower.
On the same day, Moderna dosed the first participants in a Phase 3 trial for its next-generation mRNA pandemic influenza vaccine, mRNA-1010, aimed at broader strain coverage including H5N1 threats. This advancement underscores the firm's commitment to proactive pandemic preparedness, bolstering long-term revenue potential and sentiment around its mRNA platform's versatility. These developments followed Barclays' April 2 upgrade of its price target from $25 to $48 while maintaining an Equal Weight rating, citing improved fundamentals amid litigation resolutions. The adjustment implied modest upside from then-current levels, reflecting cautious optimism.
Anticipation for Q1 2026 earnings, set for May 1, has dominated trading, with previews indicating year-over-year sales improvement from COVID vaccine demand but risks of negative EPS due to R&D spend and one-time charges like litigation. Recent quarterly revenue stood at $678 million, supported by $5.8 billion in cash reserves. Analyst notes from late April highlighted conflicted views, with some reiterating Hold ratings around $40 targets, pointing to GAAP (generally accepted accounting principles) pressures. Broader sector dynamics, including FDA leadership changes and tariff talks on imported drugs, added caution, contributing to the recent pullback despite YTD strength of over 65%. Overall, these events have linked price dips to profit-taking and macro overlays, while vaccine milestones reinforce bullish pipeline narratives.
2026 Outlook and Key Factors to Monitor
As Moderna progresses through 2026, investors should track its reiterated goal of up to 10% revenue growth, fueled by seasonal vaccine expansions like the recently approved combo shot and ongoing Phase 3 programs. Geographic initiatives, such as the February Mexico partnership for local mRNA production and clinical trials, aim to fortify supply chains and emerging market access. Oncology pipeline readouts, including skin cancer vaccines from earlier positive data, alongside rare disease and immunotherapies, represent high-upside opportunities amid a maturing mRNA ecosystem.
Risks include regulatory hurdles for novel vaccines, competition from Pfizer and others in respiratory space, and macroeconomic pressures on healthcare spending. Cost management and cash burn will be critical, given substantial R&D investments against declining COVID sales. Evolving FDA policies, H5N1 developments, and tariff impacts on drug imports warrant attention. Strategic positioning in durable immunotherapies and partnerships could drive resilience, balancing post-pandemic transitions with platform diversification.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MRNA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on April 27, 2026
MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 35 cases where MRNA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Indicator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on May 08, 2026. You may want to consider a long position or call options on MRNA as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on May 08, 2026. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
MRNA moved below its 50-day moving average on May 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MRNA crossed bearishly below the 50-day moving average on April 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.577) is normal, around the industry mean (32.192). P/E Ratio (0.000) is within average values for comparable stocks, (49.929). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (8.540) is also within normal values, averaging (323.173).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology